Pfizer on Tuesday unveiled top-line data from its Phase III MONeT trial, showing that its respiratory syncytial virus vaccine Abrysvo could induce immune protection in adults 18 to 59 years of age.
Tag Archive for: RSV
The company said in a press release that the vaccine’s efficacy against RSV-associated lower respiratory tract disease with three or more symptoms was 77.8% through season two, compared with efficacy of 88.9% after the first RSV season, which led to the shot’s U.S. approval.
White House officials on Tuesday met with representatives of Sanofi, AstraZeneca, and Thermo Fisher “and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market,” the White House said in a statement.
In an R&D event on Thursday, the French pharma is trying to win over its investors by highlighting a dozen potential blockbusters and charting strong growth for the company through 2030.
The company said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply.
The expansion, to be launched at four of the seven participating airports, comes ahead of the fall and winter months in the United States when viruses that cause respiratory diseases such as influenza and respiratory synctial virus (RSV) usually circulate more heavily.
The British drugmaker’s shot, called Arexvy, met the primary goal in the Phase-III trial of eliciting an immune response in adults of the reported age group who are at an increased risk of catching the virus due to certain underlying medical conditions, the company said.
Beyfortus, which received FDA Fast Track for this designation, is a monoclonal antibody with activity against RSV.
The Medicines and Healthcare products Regulatory Agency (MHRA) authorized GSK’s shot, called Arexvy, for active immunization to prevent lower respiratory tract disease caused by RSV in adults 60 years and older.
The vaccine maker said today it had signed a memorandum of understanding and a land collaboration agreement to work towards opportunities for it to research, develop and manufacture mRNA medicines in China.
